Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00412594
Other study ID # 2004-0223
Secondary ID NCI-2012-0139420
Status Recruiting
Phase Phase 2
First received
Last updated
Start date June 10, 2004
Est. completion date June 30, 2025

Study information

Verified date May 2024
Source M.D. Anderson Cancer Center
Contact Farhad Ravandi-Kashani
Phone 713-792-7305
Email fravandi@mdanderson.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase II trial studies the side effects and how well cladribine and rituximab work in treating patients with hairy cell leukemia. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as rituximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cladribine together with rituximab may kill more cancer cells.


Description:

PRIMARY OBJECTIVES: I. To demonstrate the efficacy in achieving complete response of combination of cladribine administered intravenously over 2 hours for 5 days followed by rituximab weekly for 8 weeks in patients with untreated or previously treated hairy cell leukemia. II. To examine the efficacy of rituximab to eradicate minimal residual disease (MRD) after cladribine therapy (as assessed by immunophenotyping of bone marrow and peripheral blood). III. To examine the effect of addition of rituximab to cladribine on the long term disease-free (DFS) and overall survival (OS) (as compared with historical controls). IV. To evaluate potential predictors of outcome including molecular and flow evaluations of MRD, as well as other potential molecular predictors such as v-raf murine sarcoma viral oncogene homolog B1 (BRAF). OUTLINE: Patients receive cladribine intravenously (IV) over 2 hours once daily (QD) on days 1-5 and rituximab IV once weekly for 8 weeks beginning on day 28 in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 1 year.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date June 30, 2025
Est. primary completion date June 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age 18 years and older - Diagnosis of hairy cell leukemia (HCL) established by bone marrow examination - Patients with relapsed disease are eligible if they have had no more than one prior therapy - Women of child-bearing potential must use birth control (oral contraceptive, barrier, abstinence or any other acceptable method) for the duration of the study - Performance status =< 3 - Creatinine less than or equal to 2.0 unless related to the disease - Bilirubin less than or equal to 3.0 - Transaminases less than or equal 3 x upper limit of normal unless related to the disease - No prior investigational agent in the 4 weeks prior to initiation of therapy Exclusion Criteria: - Unable or unwilling to sign the consent form - Known infection with human immunodeficiency virus (HIV), hepatitis B or C - Presence of active infection - Presence of central nervous system (CNS) metastases - New York Heart Association classification III or IV heart disease - Prior chemotherapy (last 4 weeks)

Study Design


Intervention

Drug:
Cladribine
Given IV
Other:
Laboratory Biomarker Analysis
Correlative studies
Biological:
Rituximab
Given IV

Locations

Country Name City State
United States M D Anderson Cancer Center Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy of rituximab on achievement of complete response after therapy with cladribine Defined as the absence of hairy cells in the bone marrow or the presence of less than 1 percent atypical cells and the disappearance of all evidence of hairy cell leukemia on physical examination. Monitored using the method of Thall, Simon, Estey as extended by Thall and Sung. At 12 weeks
Primary Monitoring the related toxicity for the therapy Grade 3-4 Monitored using the method of Thall, Simon, Estey as extended by Thall and Sung. Up to 1 year
Primary Efficacy of rituximab in eradication of minimal residual disease after cladribine therapy, assessed by immunophenotyping of bone marrow and peripheral blood The method of Thall, Simon, Estey as extended by Thall and Sung will be used for efficacy and safety monitoring. Up to 4 weeks after the last dose of rituximab
Primary Efficacy of rituximab on prolongation of event-free survival Up to 1 year
Primary Efficacy of rituximab on prolongation of overall survival Up to 1 year
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05645744 - Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
Active, not recruiting NCT03805932 - Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia Phase 1
Recruiting NCT04324112 - Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL Phase 2
Active, not recruiting NCT01711632 - BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia Phase 2
Withdrawn NCT03739606 - Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Phase 2
Active, not recruiting NCT00923013 - Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia Phase 2
Completed NCT00898079 - Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
Completed NCT01720758 - Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease N/A
Recruiting NCT04815356 - Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant Phase 1
Recruiting NCT02131753 - Therapy Optimisation for the Treatment of Hairy Cell Leukemia Phase 2/Phase 3
Completed NCT00321555 - LMB-2 to Treat Hairy Cell Leukemia Phase 2
Completed NCT00586924 - A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia Phase 1
Recruiting NCT06340737 - AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas Phase 1
Recruiting NCT05388123 - Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia Phase 2
Not yet recruiting NCT05859932 - Assessing Medical Trial Experiences of Hairy Cell Leukemia Patients
Recruiting NCT04952974 - B-cell Chronic Lymphoid Malignancies Markers
Recruiting NCT04775745 - Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. Phase 1
Completed NCT03010358 - Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Phase 1/Phase 2
Active, not recruiting NCT01059786 - Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia Phase 2
Recruiting NCT04322383 - Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant Phase 2